Company news
Astrazeneca Plc (LSE:AZN) news
Every Astrazeneca Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients...
September 13, 2026
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase I...
September 13, 2026
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-S...
September 13, 2026
AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive brea...
September 11, 2026
AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBER...
September 8, 2026
Etcamah approved in the US for HR+ breast cancer
September 7, 2026
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
September 4, 2026
AstraZeneca : Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
September 4, 2026
AstraZeneca : completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer
September 1, 2026
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
August 27, 2026
AstraZeneca prices a €2.55 billion bond offering
August 25, 2026
ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise
August 18, 2026
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-lin...
August 17, 2026
Enhertu improved PFS in 1L HER2m lung cancer
August 17, 2026
Datroway approved in EU for TNBC
July 31, 2026
AstraZeneca results: H1 and Q2 2026
July 27, 2026
AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem ...
July 27, 2026
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Br...
July 24, 2026
Etcamah approved in the EU for ER+ breast cancer
July 23, 2026
AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
July 14, 2026
Update on CARDIO-TTRansform Phase III trial
July 9, 2026
Admission of Further Securities to Trading
July 1, 2026
AstraZeneca : Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with pre...
June 29, 2026
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treate...
June 29, 2026
AstraZeneca : Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia achi...
June 28, 2026
AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative brea...
June 26, 2026
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
June 24, 2026
AstraZeneca Joins ZERO Prostate Cancer's Historic 'Blitz the Barriers' Initiative as a Founding Partner
June 15, 2026
AstraZeneca : Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy
June 15, 2026
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitiv...
June 12, 2026
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardi...
June 8, 2026
Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026
June 1, 2026
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death...
June 1, 2026
Imfinzi approved in US for early bladder cancer
May 29, 2026
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-in...
May 28, 2026
ATTR Early-Career Research Forum Opens National Call for Abstracts; Two $100,000 Wiesman Awards to Be Granted
May 28, 2026
US FDA decision date on camizestrant extended
May 27, 2026
Camizestrant recommended for breast cancer in EU
May 26, 2026
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
May 22, 2026
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
May 18, 2026
AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast an...
May 18, 2026
AstraZeneca : Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
May 15, 2026
Imfinzi + EV improves EFS & OS in bladder cancer
May 14, 2026
AstraZeneca : Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1...
May 12, 2026
FDA ODAC vote on camizestrant in breast cancer
May 1, 2026
SKF commits to a sovereign AI future through strategic partnership with Sferical AI
April 30, 2026
AstraZeneca results: Q1 2026
April 29, 2026
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
April 28, 2026
Breztri approved in the US for asthma
April 28, 2026
Saphnelo self-administration approved in the US
April 27, 2026